Biocure Technology Past Earnings Performance
Past criteria checks 4/6
Biocure Technology has been growing earnings at an average annual rate of 47.1%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been declining at an average rate of 12.8% per year.
Key information
47.1%
Earnings growth rate
48.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -12.8% |
| Return on equity | 89.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biocure Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | 2 | 1 | 0 |
| 31 Mar 23 | 0 | 0 | 1 | 0 |
| 31 Dec 22 | 0 | 0 | 1 | 0 |
| 30 Sep 22 | 0 | 2 | -1 | -1 |
| 30 Jun 22 | 0 | 1 | 0 | -1 |
| 31 Mar 22 | 0 | -1 | 1 | 0 |
| 31 Dec 21 | 0 | -2 | 2 | 0 |
| 30 Sep 21 | 0 | -6 | 3 | 3 |
| 30 Jun 21 | 0 | -5 | 2 | 3 |
| 31 Mar 21 | 0 | -4 | 2 | 1 |
| 31 Dec 20 | 0 | -3 | 1 | 2 |
| 30 Sep 20 | 0 | -3 | 2 | 1 |
| 30 Jun 20 | 0 | -3 | 2 | 1 |
| 31 Mar 20 | 0 | -5 | 3 | 1 |
| 31 Dec 19 | 0 | -5 | 3 | 1 |
| 30 Sep 19 | 0 | -4 | 3 | 1 |
| 30 Jun 19 | 0 | -4 | 3 | 1 |
| 31 Mar 19 | 0 | -6 | 5 | 1 |
| 31 Dec 18 | 0 | -7 | 5 | 1 |
| 30 Sep 18 | 0 | -9 | 5 | 1 |
| 30 Jun 18 | 0 | -9 | 4 | 1 |
| 31 Mar 18 | 0 | -5 | 1 | 1 |
| 31 Dec 17 | 0 | -5 | 1 | 0 |
| 30 Sep 17 | 0 | -3 | 1 | 1 |
| 30 Jun 17 | 0 | -3 | 1 | 1 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -2 | 1 | 0 |
Quality Earnings: BICT.F has a high level of non-cash earnings.
Growing Profit Margin: Insufficient data to determine if BICT.F's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BICT.F has become profitable over the past 5 years, growing earnings by 47.1% per year.
Accelerating Growth: BICT.F's earnings growth over the past year (178%) exceeds its 5-year average (47.1% per year).
Earnings vs Industry: BICT.F earnings growth over the past year (178%) exceeded the Biotechs industry -42.7%.
Return on Equity
High ROE: BICT.F's Return on Equity (89.9%) is considered outstanding.